1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Bio Green Med Solution, Inc.

Bio Green Med Solution, Inc.

BGMSP
Bio Green Med Solution, Inc.US flagNASDAQ Global Market
1.10
USD
- -
- -
2.40MMarket Cap
Bio Green Med Solution, Inc.
BGMSP
(NASDAQ Global Market)

Recent

price

1.10

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
1
2
2
1
- -
- -
- -
- -
- -
- -
- -
- -
1
2
Sales/Revenue/Turnover
-13,513.39
- -
-21,888.41
-1,658.12
-1,293.94
-831.79
-1,678.53
- -
-6,365.33
- -
- -
- -
- -
-6,060.24
-27,916.28
-1,128.11
-238.49
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-16
-15
-13
-10
-19
-14
-12
-7
-7
-8
-8
-18
-21
-23
-11
-3
-3
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-14,304.46
- -
-19,110.14
-936.62
-1,118.05
-737.76
-1,398.7
- -
-4,858.67
- -
- -
- -
- -
-5,370.24
-26,074.42
-401.34
-204.2
Profit Margin (%)
25
19
10
28
22
19
14
22
15
12
33
36
17
-1
-3
5
5
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
- -
- -
- -
- -
- -
- -
LT Debt
25
20
10
28
22
19
14
22
15
12
33
38
20
1
-2
7
7
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
3
5
6
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
6
6
6
Cash, Cash Equivalents & STI
4
4
3
Accounts Receivable, Net
1
1
1
Inventories
1
1
1
Total Current Liabilities
1
1
1
Payables & Accruals
1
1
1
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-84.3%
-200.47%
-414.72%
Free Cash Flow
-1.09%
6.01%
-40.3%
Net Income, GAAP
-2.53%
3.25%
-73.26%
Sales/Revenue/Turnover
- -
- -
1,637.21%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
1
1
2026
1
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Botanix Pharmaceuticals Limited (BXPHF)
Canopus Biopharma, Inc. (CBIA)
Medical System Network Co., Ltd. (4350.T)
TRxADE HEALTH, Inc. (MEDS)
Chong Kun Dang Pharmaceutical Corp. (185750.KS)
Bacil Pharma Limited (BACPHAR.BO)
Business
Bio Green Med Solution, Inc. (Nasdaq: BGMS, BGMSP) operates as a diversified company focused on the distribution, trading, and installation of protective and fire safety materials and equipment; fire protection and prevention systems; and pharmaceutical research and development targeting cancer treatments based on cell cycle, transcriptional regulation, epigenetics, and mitosis control biology. Its core offerings in fire safety include specialized products and services acquired through Fitters Sdn. Bhd., such as fire protection solutions for commercial and industrial applications, while its pharmaceutical segment historically features drug candidates like fadraciclib (a CDK9 inhibitor for solid tumors and hematological malignancies), plogosertib (a PLK1 inhibitor), seliciclib, sapacitabine, and CYC065. The company serves target markets in healthcare, construction, and industrial sectors, with primary geographic operations in Malaysia, the United States, and the United Kingdom. Founded in 1996 and headquartered in Kuala Lumpur, Malaysia, the company maintains a presence through subsidiaries and maintains Nasdaq listings for its common stock (BGMS) and 6% convertible exchangeable preferred stock (BGMSP); it was formerly known as Cyclacel Pharmaceuticals, Inc., prior to its name change in September 2022. In recent developments, Bio Green Med Solution closed the acquisition of Fitters Sdn. Bhd., a Malaysia-based fire protection specialist, on September 12, 2025, marking a strategic diversification from biopharmaceuticals into fire safety operations and generating initial product revenue of $81,000 in Q3 2025. The company sold assets related to plogosertib, including patent rights, to Tethra Biosciences Inc. on October 6, 2025, for $300,000 plus a potential $170,000 milestone payment, following the liquidation of its UK subsidiary Cyclacel Limited on January 24, 2025, and a pause in R&D spending. Additional changes include a January 2025 securities purchase agreement for approximately $5.0 million and a shift to focus on fire safety distribution while retaining pharmaceutical capabilities, with cash reserves supporting operations into Q1 2026.